Financials data is unavailable for this security.
Cash flow in SEKView more
In 2023, XSpray Pharma AB (publ) increased its cash reserves by 38.39%, or 46.14m. Cash Flow from Financing totalled 315.59m or -- of revenues. In addition the company used 203.28m for operations while cash used for investing totalled 65.88m.
Cash flow per share | -6.76 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 19.79 |
---|---|
Tangible book value per share | 6.50 |
More ▼
Balance sheet in SEKView more
Current ratio | 4.67 |
---|---|
Quick ratio | 3.50 |
Total debt/total equity | 0.0521 |
---|---|
Total debt/total capital | 0.0496 |
More ▼